No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in Bangkok, Thailand, in 1982, Mega Lifesciences Public Company Limited, a subsidiary of Unistretch Limited, operates as a comprehensive pharmaceutical and wellness enterprise. Its primary activities encompass the development, promotion, and distribution of a broad spectrum of health-related products, including nutritional supplements, prescription medicines, over-the-counter (OTC) remedies, botanical solutions, vitamins, and everyday consumer goods. The company structures its operations across three main divisions: Brands, Distribution, and Original Equipment Manufacture. Mega Lifesciences offers an extensive array of complementary medicines targeting various health concerns such as bone and joint health, pediatric care, diabetes management, cardiovascular support, digestive and liver wellness, skin health, weight management, overall well-being, men's and women's specific needs, and sports nutrition. Its OTC portfolio addresses common issues like gastrointestinal discomfort and pain. Furthermore, the prescription drug division covers crucial therapeutic areas including iron deficiency, anticoagulation, diabetology, cardiology, dermatology, gastroenterology, neurology, pain relief, osteoporosis, respiratory conditions, urology, oncology, and nephrology. Beyond its proprietary product lines, the company also provides third-party logistical and marketing services. Additionally, Mega Lifesciences is involved in managing wellness centers and offers specialized services in software design, development, and related technological solutions. The company maintains a significant global footprint, with operations spanning the Asia Pacific region, the Middle East, Africa, and the Commonwealth of Independent States.
www.megawecare.comNo one on the platform currently holds MEGA.BK.
No tracked institution reports a position in MEGA.BK as of their last filing.
No one on the platform has traded MEGA.BK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 34.9% | 35.4% | 28.1% | — | — | — |
| Rev. Growth % | -7.8% | 2.4% | ||||
| Profit Margin % | 13.5% | 13.5% | 12.1% | |||
| Free Cash Flow Margin % | 15.1% | 13.7% | 10.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $14.8B | +1.3% | $2.64 | $2.53–$2.74 | — | 5 |
| 2027 | $15.6B | +5.6% | $2.84 | $2.73–$3.03 | — | 6 |
| 2028 | $16.4B | +5.3% | $3.08 | $2.99–$3.27 | — | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $0.60 | $0.58 | -3.3% |
| 2026-05-13 | $0.60 | $0.69 | +15.6% |
| 2026-02-24 | $0.65 | $0.66 | +1.9% |
| 2025-11-13 | $0.35 | $0.57 | +61.3% |
| 2025-08-14 | $0.68 | $0.45 | -34.2% |
| 2025-05-14 | $0.41 | $0.52 | +25.3% |
| 2025-02-24 | $0.67 | $0.73 | +9.4% |
| 2024-11-12 | $0.51 | $0.44 | -13.7% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| MEGA.BKMega Lifesciences Public Company Limited | $36.25 | +0.00% | $31.6B | — |
| BCH.BKBangkok Chain Hospital Public Company Limited | $11.00 | +0.00% | $27.4B | — |
| CHG.BKChularat Hospital Public Company Limited | $1.57 | +1.95% | $17.3B | — |
| PR9.BKPraram 9 Hospital Public Company Limited | $19.40 | +0.00% | $15.3B | — |
| RAM.BKRamkhamhaeng Hospital Public Company Limited |
| $17.60 |
| +0.57% |
| $21.1B |
| — |
| SKR.BKSikarin Public Company Limited | $7.80 | -0.64% | $15.9B | — |
| TNH.BKThai Nakarin Hospital Public Company Limited | $28.50 | +0.00% | $5.1B | — |
Source: Financial Modeling Prep · peers by sector/industry